Cardiovascular Diabetology (Nov 2011)

Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction

  • Fousteris Evangelos,
  • Melidonis Andreas,
  • Panoutsopoulos George,
  • Tzirogiannis Konstantinos,
  • Foussas Stefanos,
  • Theodosis-Georgilas Anastasios,
  • Tzerefos Stavros,
  • Matsagos Spiridon,
  • Boutati Eleni,
  • Economopoulos Theofanis,
  • Dimitriadis George,
  • Raptis Sotirios

DOI
https://doi.org/10.1186/1475-2840-10-101
Journal volume & issue
Vol. 10, no. 1
p. 101

Abstract

Read online

Abstract Background Soluble ST2, a member of the of the Toll/IL-1 superfamily, is a novel biomarker with exceptional predictive value in heart failure and myocardial infarction- related mortality as well as in acute dyspneic states. Soluble ST2 is considered a decoy receptor of IL 33 that blocks the protective effects of the cytokine in atherosclerosis and cardiac remodeling. In the present study we investigated the differences in the levels of soluble ST2, BNP and hs-CRP between healthy controls and patients with type 2 diabetes with and without left ventricular diastolic dysfunction. A secondary aim was to investigate correlations between sST2 and other biomarkers of type 2 diabetes, such as HbA1c. Methods 158 volunteers were recruited and underwent a complete Doppler-echocardiographic evaluation of both systolic & diastolic cardiac function. All subjects with ejection fraction Results Patients with type 2 diabetes with (p Conclusions Patients with type 2 diabetes exhibit higher sST2 levels compared to healthy controls. The presence of LVDD in patients with type 2 diabetes is associated with even higher sST2 levels. A significant correlation between glycemic control and sST2 levels was also revealed.

Keywords